Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Hypereosinophilic Syndrome (HES) Study for Children

Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 years with Hypereosinophilic Syndrome

physician listening to girls heart

 

AGE: 6 - 17 years old
SEX AT BIRTH: All
TYPE: Interventional Drug Study
HEALTHY PARTICIPANTS: No
CONDITION: Hypereosinophilic Syndrome (HES)
LOCATION: University Hospitals Rainbow Babies & Children’s

Learn More About This Research Study

For more information, please contact study coordinator, Erica Denallo at 216-286-7453 and leave a message or click the link to the study survey below.

Study Purpose

The purpose of this study is to learn more about Hypereosinophilic syndrome (HES) and to test the efficacy and safety of an investigational drug, mepolizumab on children (aged 6 to 11 years) and teenagers (aged 12 to 17 years) who have and are being treated for HES. This medication is already FDA- approved for children and adults ages 12 and up with HES.

Who Can Participate

Participants between the ages of 6 and 17 years of age diagnosed with Hypereosinophilic Syndrome may be eligible for this study.

I'm not a robot

Study ID